publication venue for
- Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.. 13. 2018
- Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.. 11. 2016
- Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.. 10. 2015
- Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.. 10. 2014
- Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept.. 8. 2013
- Targeting insulin-like growth factor type 1 receptor in cancer therapy. 2009